© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The FDA has approved Olysio (simeprevir) to treat those with genotype 1 of hepatitis C who have compensated liver disease, including...
A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.
Simeprevir demonstrated greater efficacy than the current line of hepatitis C drugs among those with genotype and who had compensated liver d...
Janssen’s investigational hepatitis C drug simeprevir received a unanimous recommendation for approval from a U.S. FDA panel.
The FDA has given Janssen Research and Development priority review status for its investigational hepatitis C therapy simeprevir.
Janssen has submitted its investigational agent simeprevir to the U.S. Food and Drug Administration for approval for treatment of genotype.
Adding Janssen Therapeutics’ TMC435, a once-daily experimental hepatitis C virus (HCV) protease inhibitor, to pegylated interferon and ribavir...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
